Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Jubilant Pharmova Limited ( (IN:JUBLPHARMA) ) is now available.
Jubilant Pharmova Limited announced that its subsidiary, Jubilant Biosys Innovative Research Services Pte Limited (JBIRSPL), has acquired an 80% equity stake in JASMIN, a French company newly incorporated by Pierre Fabre SA, with the remaining 20% retained by Pierre Fabre. The transaction involves JASMIN acquiring Pierre Fabre’s R&D Centre in Saint Julien, France, and comes with a Shareholders’ Agreement and other transition agreements. This strategic acquisition marks an expansion of Jubilant Pharmova’s research and development capabilities in Europe and strengthens its position in the pharmaceutical industry.
More about Jubilant Pharmova Limited
Jubilant Pharmova Limited operates in the pharmaceutical industry, focusing on research and development services. It primarily provides innovative research services through its subsidiary Jubilant Biosys Limited.
YTD Price Performance: -16.71%
Average Trading Volume: 25,336
Current Market Cap: 147B INR
For detailed information about JUBLPHARMA stock, go to TipRanks’ Stock Analysis page.